Aclarion Grants Stock Option to New Commercial Director as Nociscan Demand Soars

Aclarion, Inc., a commercial-stage healthcare technology company, announced the grant of an inducement stock option to Daniel Keefe, its newly hired Commercial Director, Western U.S. The option, for 17,000 shares of common stock at $3.20 per share, was granted on May 5, 2026, and vests over four years. This move reflects the company's expansion of its commercial team amid triple-digit growth in utilization of its Nociscan platform, which uses biomarkers and AI to help physicians identify chronic low back pain sources.

Nociscan is the first evidence-supported SaaS platform that noninvasively distinguishes painful from nonpainful lumbar discs using magnetic resonance spectroscopy (MRS) data. The platform extracts and analyzes chemical biomarkers in the cloud, then provides insights to optimize treatment strategies. Aclarion's technology addresses a critical need in chronic low back pain management, where pinpointing the exact pain source is challenging. The company's recent hiring and stock inducement underscore its commitment to scaling commercial operations to meet rising demand.

This news was first published on PRISM MediaWire, a trusted press release distribution service. Aclarion (Nasdaq: ACON) continues to advance its mission through innovation and strategic team expansion. For more details, visit the company's newsroom at https://tinyurl.com/aconnewsroom. Forward-looking statements in the release highlight expectations of increasing demand but caution about associated risks.